TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05899166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet, food delivery and education
Description: Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard diet, food delivery and education
Description: Meals and groceries will be delivered and participants will receive education on nutrition, meal preparation, and diabetes care strategies. Participants will consume study-prescribed foods exclusively.
Study: NCT06200896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnets used to Create A Compression Anastomosis
Description: Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnets used to Create A Compression Anastomosis
Description: Self Forming Magnets used to Create A Compression Anastomosis connecting the Duodenum to the ileal in Post Sleeve Gastrectomy Patients and Jejunum to jejunum in Roux-en-Y patients.
Study: NCT05412498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BR-30
Description: Battle rope training exercises will be performed for 30 seconds and the training volume will be consisted of 1 repetition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BR-45
Description: Battle rope training exercises will be performed for 45 seconds and the training volume will be consisted of 1 repetition.
Study: NCT05487833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: insulin
Description: 5% glucose in 0.9% NaCl with 4 IU of short acting insulin per 500 ml added, infused at a rate determined by the treating physician, treatment duration: 18 hours

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: infusion of a balanced solution, infused at a rate determined by the treating physician, treatment duration: 18 hours
Study: NCT05409911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration
Study: NCT06047145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: 1 capsule daily for 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 84 days
Study: NCT06386497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nocturnal translational vestibular stimulation
Description: Nocturnal (overnight) translational vestibular stimulation applied by the rocking bed (Somnomat Casa) for two months in patients familiar home environment.
Study: NCT06386783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl HCl
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
Study: NCT05351164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
Study: NCT05492591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b
Description: Injecting different doses of the peginterferon α1b into different groups of subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b
Description: Injecting different doses of the peginterferon α1b into different groups of subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b
Description: Injecting different doses of the peginterferon α1b into different groups of subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b with valacyclovir
Description: Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b with valacyclovir
Description: Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir is a positive control drug.
Study: NCT06165198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop tACS stimulation based on addiction-induced states
Description: We conducted a longitudinal controlled study of closed-loop tACS interventions among MA dependents.This involved implementing interventions based on addiction-induced states through closed-loop tACS stimulation, randomized time-point stimulation, and traditional continuous stimulation.
Study: NCT06060340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: class II furcation defects management using propolis
Description: A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect.
Study: NCT05121805

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Snare tip soft coagulation
Description: Thermal ablation of the entire resection margin
Study: NCT06091098

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic CO2
Description: 2% inspired CO2 for 2-4 breaths

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CO2
Description: 2% inspired CO2 for 2-4 breaths

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CO2
Description: Air

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CO2
Description: Air
Study: NCT06199427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 7 mg/m2 from day +5 after HSCT
Study: NCT01562652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)
Study: NCT04714190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate Tablets
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study: NCT04824742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PDT + radical surgery
Description: Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: Patients with cholangiocarcinoma will only receive radical surgery
Study: NCT04728698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: 1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of placebo will be administered
Study: NCT04668209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silmitasertib
Description: Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
Study: NCT06163027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shotblocker
Description: Shotblocher will be administered during spinal needle injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Shotblocker(Plasebo)
Description: The back side of the shotblocher will be applied during spinal needle injection
Study: NCT05964985

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: After the induction of anesthesia, normal saline is used for bilateral quadratus lumborum block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: After the induction of anesthesia, 0.375% ropivacaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound lidocaine
Description: After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound lidocaine
Description: After the induction of anesthesia, 0.6% compound lidocaine is used for bilateral quadratus lumborum block in a volume of 20 mL of each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: After the induction of anesthesia, 0.4mg/kg esketamine is used for bilateral quadratus lumborum block
Study: NCT04840589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT06456463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
Study: NCT05160480

Intervention type: DIAGNOSTIC_TEST
Intervention: Total-body PET imaging
Description: Total-body PET imaging at different timepoints
Study: NCT06520514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spesolimab
Description: Spesolimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study: NCT06242275

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Alpha-amylase
Description: Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab.

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary Alpha-amylase
Description: Saliva samples will be obtained using a saliva collection system and salivary Alpha-amylase (SAA) level will be measured preoperatively, immediately postoperative, at the end of the 1st, 2nd, and 3rd postoperative days. For sampling, the swab will be placed into the patient's mouth for 2-5min by a specially trained nurse.~A minimum of 0.2mL of saliva will be needed as per the manufacturer's recommendations to saturate the swab.
Study: NCT06011603

Intervention type: DEVICE
Group type: OTHER
Intervention: Prineo dressing
Description: Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.

Intervention type: DEVICE
Group type: OTHER
Intervention: Prineo dressing
Description: Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
Study: NCT06364215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Farapulse PFA, Pulmonary Vein Isolation alone
Description: Ablation of the pulmonary veins for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Farapulse PFA, Pulmonary Vein Isolation and Left atrial Posterior Wall Isolation
Description: Ablation of the pulmonary veins and the left atrium posterior wall for the treatment of Paroxysmal Atrial Fibrillation using pulsed field ablation.
Study: NCT05974202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active H7-coil repetitive transcranial magnetic stimulation (rTMS)
Description: A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)
Description: A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
Study: NCT05601726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABD-3001
Description: Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABD-3001
Description: For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days.
Study: NCT04842643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% infusion
Description: IGSC 20% infusion,
Study: NCT06014034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programmed Weaning From Noninvasive Mechanical Ventilation
Description: Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
Study: NCT06435429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally
Study: NCT05202860

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: (Gardasil 9 human papilloma vaccine)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO vaccine
Description: Isotonic saltwater sham vaccine
Study: NCT06541847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX-1502
Description: Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
Study: NCT05976945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
Study: NCT05083442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (placebo)
Description: Use of sham (placebo) option
Study: NCT05816551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia Trial
Description: Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia Trial
Description: Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Trial
Description: Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Trial
Description: Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol.
Study: NCT05302765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Intravenous Fluids
Description: Administration of normal saline intravenous fluids (20 milliliters/kilogram).
Study: NCT06333340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.